anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention uses micro and nano segmentation to create targeted digital content, in the form of segment specific static ads, pictures, carousel, mobile new feeds, video, canvas and other ad types. For example, if the motivation for a health change in an individual is for the sake of their family, specific images or video from social media may be effective in tying the rationale for the change to the messaging. This content can then be delivered is static ads, in carousels or other media options. The content is targeted to a specific user using conventional and unconventional social media targeting systems to assist with the creation of custom campaign delivered over social media for the purposes of influencing positive health behavior. Data such as including browsing history, social media posts, Interests, Gender, Relationship Status, Educational Status, Age, Location, Language as well as user specific medical and non medical data sources including but not limited to demographics, medical history, treatments, credit score data and report information etc. will be used with a machine learning algorithm to create digital patient phenotypes or cohorts and associate them with the probability that a given digital media campaign will be maximally affect to influence individuals in that cohort to affect the desired behavior change. Example may include what graphic elements are included in the digital materials, the frequency of delivering that content, the channels use etc.
Deflazacort oral suspension contains benzyl alcohol and is not approved for use in pediatric patients less than 2 years of age. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs, including deflazacort oral suspension. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations.

When prescribing deflazacort oral suspension, consider the combined daily metabolic load of benzyl alcohol from all sources, including deflazacort oral suspension (Deflazacort oral suspension contains 10.45 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known. At the recommended dose of 0.9 mg/kg/day of deflazacort oral suspension, patients would receive approximately 0.4 mg/kg/day of benzyl alcohol [see Use in Specific Populations (8.4)].
PURPOSE:To make it possible to industrially prepare a liposome, by spray-drying a solution prepared by dissolving a liposome membrane componential substance in a volatile org. solvent to prepare a uniform mixture and subsequently dispersing said mixture throughout an aqueous solvent. CONSTITUTION:A liposome membrane componential substance pref. consisting of 1pt.wt. of (a) lipid (e.g., phosphatidylcholine), 0-1pt.wt. of (b) sterols (e.g., cholesterol) and 0-0.2pt.wt. of (c) a charge substance (e.g., ganglioside) is dissolved in a volatile org. solvent to prepare a solution which is, in turn, spray- dried to obtain a uniform mixture wherein the liposome membrane componential substances are uniformly mixed. Subsequently, an aqueous solvent is added to said uniform mixture to swell the membrane componential substances and these substances are sufficiently dispersed using an emulsifying apparatus to prepare a liposome suspension. In dissolving the membrane componential substances in the volatile org. solvent, if a nuclear substance (e.g., sorbitol) insoluble in the volatile org. solvent is added, a powder having a particle size still more small is often obtained.
This study explores the significant correlation between frailty and an elevated risk of mortality in COVID-19 patients, suggesting that increased frailty screening could enhance disease management and optimize resource distribution. An analysis of peer-reviewed papers on frailty and cardiovascular diseases (CVD) over a ten-year period reveals a peak of 4480 articles from September 2021 to September 2022. The literature review conducted on frailty and CVD highlights the high prevalence of frailty in older adults with CVD and its role as a predictor of cardiovascular death. The study suggests that frailty can inform treatment decisions, offering more personalized care. However, standardizing frailty assessment in clinical practice and trials is needed. The impact of frailty on coronary artery disease, peripheral artery disease, and atrial fibrillation requires further research. The study also discusses the increasing global burden of CVD among older adults due to aging populations and improved care. It highlights the challenges posed by older age, multiple comorbidities, polypharmacy, frailty, and adverse noncardiovascular outcomes. The review focuses on geriatric conditions that significantly impacted health status, quality of life, and overall prognosis. The study concludes that frailty significantly increases the risk of CVD events and major adverse cardiovascular events in older adults without prior CVD. Screening for frailty could help identify those at higher risk and facilitate targeted preventive measures.
Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
PURPOSE: Co-prevalence of abdominal aortic aneurysm (AAA) and cancer poses a unique challenge in medical care since both diseases and their respective therapies might interact. Recently, reduced AAA growth rates were observed in cancer patients that received radiation therapy (RT). The purpose of this study was to perform a fine-grained analysis of the effects of RT on AAA growth with respect to direct (infield) and out-of-field (outfield) radiation exposure, and radiation dose-dependency.
METHODS: A retrospective single-center analysis identified patients with AAA, cancer, and RT. Clinical data, radiation plans, and aneurysm diameters were analyzed. The total dose of radiation to each aneurysm was computed. AAA growth under infield and outfield exposure was compared to patients with AAA and cancer that did not receive RT (no-RT control) and to an external noncancer AAA reference cohort.
RESULTS: Between 2003 and 2020, a total of 38 AAA patients who had received well-documented RT for their malignancy were identified. AAA growth was considerably reduced for infield patients (n = 18) compared to outfield patients (n = 20), albeit not significantly (0.8 ± 1.0 vs. 1.3 ± 1.6 mm/year, p = 0.28). Overall, annual AAA growth in RT patients was lower compared to no-RT control patients (1.1 ± 1.5 vs. 1.8 ± 2.2 mm/year, p = 0.06) and significantly reduced compared to the reference cohort (1.1 ± 1.5 vs. 2.7 ± 2.1 mm/year, p < 0.001). The pattern of AAA growth reduction due to RT was corroborated in linear regression analyses correcting for initial AAA diameter. A further investigation with respect to dose-dependency of radiation effects on AAA growth, however, revealed no apparent association.
CONCLUSION: In this study, both infield and outfield radiation exposure were associated with reduced AAA growth. This finding warrants further investigation, both in a larger scale clinical cohort and on a molecular level.
Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably  131 I or  125 I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anti-cancer active agent, for example  131 I,  125 I,  124 I, or  123 I, or a chemotherapeutic agent.
1,056,206. Change-speed control. FORD MOTOR CO. Ltd. July 16, 1965, No. 30239/65. Heading F2D. A gear selector mechanisn comprises a rod 1, having a collar 25 and pin 27, which is rotatable to engage pin 27 in a recess 13 or 21 in striker members 3, 5 slidable on rod 1 or reverse gear lever 19 and then axially slidable to move members 3, 5 on lever 19 to engage the desired gear. An interlock member 29, which may be of glass reinforced plastic, is rotatable on collar 25 and engages grooves 31 in the gear-box casing to prevent axial movement; the pin 27 in its neutral position engages a slot 33 in member 29 and rotates it so that portion 35 engages the recesses 13, 21 of the members not to be moved by pin 27 and so prevent these members from axial movement. To prevent inadvertent engagement of reverse gear a spring-loaded ball 39 normally engages in a groove 45 in member 29 but has to be forced out of this groove and into bore 41 when reverse is engaged.
The invention relates to the field of medical diagnostics. A medical decision support system comprises an interface unit, a data input unit, a decision storage unit for each of the therapeutic fields, a computer unit, a unit that checks for contradictions in the input data, a decision output unit and a treatment recommendations unit. The interface unit receives data and exchanges data with the data input unit, the decision output unit and the treatment recommendations unit. The data input unit transmits data to the unit that checks for contradictions in the input data, and the computer unit calculates the weighting coefficients assigned to the symptoms for each disease and the scores in favor of specific diseases. The decision output unit produces information on all of the reference medical history, highlighting signs identified during examination of the patient and allowing each reference disease model to be compared and diseases to be grouped by human body organs or systems. Moreover, the treatment recommendations unit is capable of receiving data from the data input unit and the decision output unit and displaying an optimum treatment plan on the interface unit.
Participants will be asked to fill out several short paper and pencil tests to assess your response to the treatment (10 to 15 minutes) pre-intervention and immediately post-intervention while on the Inpatient Psychiatric Unit (IPU), as well as a follow-up phone call or mail one month after discharge from the IPU. All participants will receive the IPU's normal standard of care treatment (for study purposes this called treatment as usual).
Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
(-)-Epicatechin (EPI) is beneficial for cardiovascular health. Trimethylamine N-oxide (TMAO), a gut microbe-derived food metabolite, is strongly associated with the risk of cardiovascular diseases. However, the effects and underlying mechanisms of EPI on TMAO-induced cardiac hypertrophy remain unclear. This study aimed to determine whether EPI inhibits TMAO-induced cardiac hypertrophy. Plasma levels of TMAO in control participants and patients with cardiac hypertrophy were measured and analyzed. Male C57BL/6 mice were randomly divided into control group, TMAO group, EPI group and TMAO + EPI group. According to the groups assignments, mice received intraperitoneal (i.p.) injection of normal saline or i.p. injection of TMAO (150 mg/kg/day) for 14 days. The EPI group was given intragastric (i.g.) administration of EPI alone (1 mg/kg/day) for 21 days, and TMAO + EPI group received i.g. administration of EPI for 7 days before starting i.p. injection of TMAO, continuing until the end of the TMAO treatment. Histological analyses of the mice's hearts was accessed by H&E and Masson staining. In vitro, H9c2 cells were induced to hypertrophy by TMAO (10 µM) for 24 h and were pre-treated with or without EPI (10 µM) for 1 h. Protein level of cardiac hypertrophy markers and Sp1/SIRT1/SUMO1 pathway were determined by western blot. The plasma level of TMAO was 2.66 ± 1.59 μmol/L in patients with cardiac hypertrophy and 0.62 ± 0.30 μmol/L in control participants. EPI attenuated TMAO-induced hypertrophy in H9c2 cells. In vivo, TMAO induced cardiac hypertrophy and impaired the cardiac function of mice. Pathological staining showed that TMAO induced cardiac hypertrophy and collagen deposition in mice. EPI treatment improved the cardiac function, inhibited the myocardial hypertrophy induced by TMAO. EPI significantly attenuated the TMAO-induced upregulation of ANP and BNP and the downregulation of SP1, SIRT1 and SUMO1 in vivo and in vitro. EPI may suppress TMAO-induced cardiac hypertrophy by activating the Sp1/SIRT1/SUMO1 signaling pathway.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic (scarring) disease of the lung of unknown cause. Approximately 100,000 Americans will die from IPF this year. There is no cure for IPF other than lung transplantation, which only 1% of patients will receive. Recently, 2 drugs were approved by the FDA to slow the rate of decline in lung function among patients with IPF. These drugs do not decrease symptoms or improve quality of life.

Symptoms of IPF include shortness of breath, cough, and fatigue, all of which may also adversely affect quality of life. Yoga is a practice of exercises, including breathing exercises, that has been shown to be relatively safe and to improve quality of life in some patients with other advanced lung diseases. We hypothesize that regular yoga and breathing exercises, specifically designed for patients with Idiopathic Pulmonary Fibrosis, over a period of 12 weeks will lead to improved quality of life as measured by several different quality of life questionnaires.
Rift Valley Fever (RVF) is a mosquito-borne disease in Africa that affects both humans and animals. The disease poses a significant endemic disease threat, and the etiologic agent (RVF virus) possesses physical and biochemical characteristics that have resulted in its classification as a Category A Agent. Historically, this disease was confined to Africa. In September 2000, however, RVF appeared in the western part of the Kingdom of Saudi Arabia (843 cases with 114 deaths) and in Yemen (1,087 suspected cases with 121 deaths). It is thought that Rift Valley fever was introduced into this new geographic area through importation of infected livestock from Djibouti. Mosquito transmission has been subsequently demonstrated in these areas, suggesting that the disease may have become permanently established. A safe and effective RVF vaccine capable of inducing protective immunity after a single injection is urgently needed. Currently, no drug is available that will alter the course of the disease in humans or animals, nor is any licensed vaccine for RVF approved for human use. This protocol is an open-label, Phase II study to assess the safety, immunogenicity and genetic stability of RVF MP-12 vaccine in humans. The objectives of this study are to collect safety and immunogenicity data for an intramuscular (IM) injection of live, attenuated, mutagenized RVF 12th mutagenesis passage (MP-12) vaccine and characterize isolates of the Rift Valley fever (RVF) MP-12 vaccine recovered from blood of vaccinated volunteers using in vitro systems to evaluate genetic stability. A total of 20 volunteers will be recruited from among military and civilian persons at and around USAMRIID and from the general population in and around Frederick, Maryland, who expect to remain in the area for the duration of the study. Volunteers will be vaccinated with undiluted RVF MP-12 vaccine. Safety will be evaluated by recording the frequency and severity of clinical reactions to the vaccine, as well as by measuring complete blood counts and selected serum biochemistry (enzyme) values. Immunogenicity will be evaluated by measuring 80% plaque reduction neutralization (PRNT80) antibodies to RVF virus for periods up to 1 year following vaccination. Genetic stability of the vaccine will be evaluated by examining isolates recovered from blood of vaccinated volunteers by molecular sequencing techniques, and comparing these findings with those from the vaccine virus inoculum. Subjects will participate in the study for up to 1 year.
A homogeneous composition of an essential oil and essence water is provided. The essential oil may be derived from the plant matter through an extraction process, such as steam-based distillation. The essence water may be a byproduct of the extraction of the essential oil from plant matter. The homogeneous composition may be formed by breaking down the components of the essential oil into small particles and distributing them evenly throughout the essence water to form a colloid. The essential oil and the essence water may be derived from the same plant matter or different plant matter. The homogeneous composition may be topically applied or ingested for therapeutic or nutritional benefits.
This study is an open randomized controlled trial of 4 weeks duration. The intervention is a novel urinary catheter with an electromagnetic therapy to prevent catheter associated infections. The catheter is used in patients which require longterm urinary catheterization over at least 1 month.

The endpoint is bacteriological exam and the laboratory is blinded to the therapy status. Weekly urinary cultures are drawn and a sonication culture of the catheter tip is performed to detect and characterize the biofilm. A colonization rate of \>95% is anticipated in the control arm. Therefore a 50% reduction in colonization can be detected with 54 patients, a 90% reduction in colonization can be detected with 20 patients with a power of 0.9.
BACKGROUND: Despite low mortality for elective procedures in the United States and developed countries, some patients have unexpected care escalations (UCE) following post-anesthesia care unit (PACU) discharge. Studies indicate patient risk factors for UCE, but determining which factors are most important is unclear. Machine learning (ML) can predict clinical events. We hypothesized that ML could predict patient UCE after PACU discharge in surgical patients and identify specific risk factors.
METHODS: We conducted a single center, retrospective analysis of all patients undergoing non-cardiac surgery (elective and emergent). We collected data from pre-operative visits, intra-operative records, PACU admissions, and the rate of UCE. We trained a ML model with this data and tested the model on an independent data set to determine its efficacy. Finally, we evaluated the individual patient and clinical factors most likely to predict UCE risk.
RESULTS: Our study revealed that ML could predict UCE risk which was approximately 5% in both the training and testing groups. We were able to identify patient risk factors such as patient vital signs, emergent procedure, ASA Status, and non-surgical anesthesia time as significant variable. We plotted Shapley values for significant variables for each patient to help determine which of these variables had the greatest effect on UCE risk. Of note, the UCE risk factors identified frequently by ML were in alignment with anesthesiologist clinical practice and the current literature.
CONCLUSIONS: We used ML to analyze data from a single-center, retrospective cohort of non-cardiac surgical patients, some of whom had an UCE. ML assigned risk prediction for patients to have UCE and determined perioperative factors associated with increased risk. We advocate to use ML to augment anesthesiologist clinical decision-making, help decide proper disposition from the PACU, and ensure the safest possible care of our patients.
TRPM2 is a calcium permeable channel activated by ADPR metabolites and oxidative stress. TRPM2 contributes to neuronal injury in the brain caused by stroke and cardiac arrest among other diseases including pain, inflammation, and cancer. However, the lack of specific inhibitors hinders the study of TRPM2 in brain pathophysiology. Presented is the design of a novel TRPM2 antagonist, tatM2NX and truncated variants thereof, which prevents ligand binding and TRPM2 activation. Mutagenesis of tatM2NX was used to determine the structure- activity relationship and antagonistic mechanism on TRPM2 using whole-cell patch clamp and Ca 2+  imaging in HEK293 cells with stable human TRPM2 expression, showing that tatM2NX inhibits over 90% of TRPM2 channel currents at concentrations as low as 2μΜ. Moreover, tatM2NX is a potent antagonist with an IC 50  of 396nM. These results from tatM2NX mutagenesis demonstrate that specific residues within the tatM2NX C-terminus are required to confer antagonism on TRPM2. Therefore, truncated residues of the C-terminus of the peptide tatM2NX represent a new and potent therapeutic for a number of conditions, including neuronal injury and traumatic brain injury.
UNLABELLED: Oral microbial dysbiosis has been associated with periodontitis in studies using 16S rRNA gene sequencing analysis. However, this technology is not sufficient to consistently separate the bacterial species to species level, and reproducible oral microbiome signatures are scarce. Obtaining these signatures would significantly enhance our understanding of the underlying pathophysiological processes of this condition and foster the development of improved therapeutic strategies, potentially personalized to individual patients. Here, we sequenced newly collected samples from 24 patients with periodontitis, and we collected available oral microbiome data from 24 samples in patients with periodontitis and from 214 samples in healthy individuals (n = 262). Data were harmonized, and we performed a pooled analysis of individual patient data. By metagenomic sequencing of the plaque microbiome, we found microbial signatures for periodontitis and defined a periodontitis-related complex, composed by the most discriminative bacteria. A simple two-factor decision tree, based on Tannerella forsythia and Fretibacterium fastidiosum, was associated with periodontitis with high accuracy (area under the curve: 0.94). Altogether, we defined robust oral microbiome signatures relevant to the pathophysiology of periodontitis that can help define promising targets for microbiome therapeutic modulation when caring for patients with periodontitis.
IMPORTANCE: Oral microbial dysbiosis has been associated with periodontitis in studies using 16S rRNA gene sequencing analysis. However, this technology is not sufficient to consistently separate the bacterial species to species level, and reproducible oral microbiome signatures are scarce. Here, using ultra-deep metagenomic sequencing and machine learning tools, we defined a simple two-factor decision tree, based on Tannerella forsythia and Fretibacterium fastidiosum, that was highly associated with periodontitis. Altogether, we defined robust oral microbiome signatures relevant to the pathophysiology of periodontitis that can help define promising targets for microbiome therapeutic modulation when caring for patients with periodontitis.